Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 18fludarabine 15Dexamethasone 15Nivolumab 14Gemcitabine 14Bevacizumab 14Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10Docetaxel 10Cisplatin 10venetoclax 9Rituximab 9Pemetrexed 9Ipilimumab 9Prednisone 8Lenalidomide 8Fluorouracil 8blinatumomab 7Vincristine 7Radiotherapy 7Oxaliplatin 7Capecitabine 7olaparib 6lenvatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Decitabine × 30 days × Clear all
NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡